Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scripts Update for Week Ending 08/03
ATH in NRx Market Share
V
TRx: 40,171 {vs 40,285; -0.28%} Sector -0.11% --- 2nd ATH
NRx: 17,240 {vs 18,440; -6.51%} Sector -8.47% --- 4th ATH
Ref: 22,931 {vs 21,845; +4.97%} Sector +6.61% --- ATH
GenL
TRx: 49,797 {vs 49,738; +0.12%}
NRx: 19,587 {vs 21,810; -10.19%}
L
TRx: 910 {vs 958; -5.01%}
NRx: 306 {vs 320; -4.38%}
V TRx Market Share: 44.20% vs 44.28% --- 2nd ATH
V NRx Market Share: 46.43% vs 45.45% --- ATH
V Ref Market Share: 42.67% vs 43.33% --- 2nd ATH
Scripts Historical Performance for the same period in previous year
V // GL // Sector
TRx 2016: -4.34% // -5.10% // -5.13%
TRx 2017: -0.80% // -2.18% // -1.81%
TRx 2018: -0.17% // -0.78% // -0.63%
TRx 2019: -0.28% // +0.12% // -0.11%
NRx 2016: -6.37% // -3.96% // -4.69%
NRx 2017: +1.23% // +1.31% // +1.19%
NRx 2018: -1.11% // -1.66% // -1.19%
NRx 2019: -6.51% // -10.19% // -8.47%
February-2019 vs. February-2018 (Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board, more than 50% increase in TRx & almost 80% increase in NRx and we’re still in Q1 which is historically a slow Quarter
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year) and at the same time increasing its own Market Share
V
TRx: 151,848 {vs 99,159; +53.14%} – Sector +9.09% -- 2nd ATH
NRx: 69,891 {vs 39,217; +78.22%} – Sector +23.74% -- ATH
Ref: 81,957 {vs 59,942; +36.73%} – Sector -0.37% -- 3rd ATH
Gen L
TRx: 194,820 {vs 206,316; -5.57%}
NRx: 84,760 {vs 79,942; +6.03%}
L
TRx: 3,750 {vs 15,733; -76.16%}
NRx: 1,333 {vs 6,901; -80.68%}
V Feb-2019 Retail ONLY TRx Market Share: 43.33% vs 30.87% in Feb-2018 --- ATH
V Feb-2019 Retail ONLY NRx Market Share: 44.81% vs 31.11% in Feb-2018 --- ATH
V Feb-2019 Retail ONLY Ref Market Share: 42.15% vs 30.72% in Feb-2018 --- ATH
Total Monthly Retail ONLY Data February-2019
Amazing Numbers considering that February was 3 Days Less than January -- ATH NRx Numbers & Across the Board in Market Share
V
TRx: 151,848 {vs 151,870; -0.01%} – Sector -10.19% -- 2nd ATH
NRx: 69,891 {vs 65,725; +6.34%} – Sector -5.26% -- ATH
Ref: 81,957 {vs 86,145; -4.86%} – Sector -13.79% -- 3rd ATH
Gen L
TRx: 194,820 {vs 234,040; -16.76%}
NRx: 84,760 {vs 97,351; -12.93%}
L
TRx: 3,750 {vs 4,250; -11.76%}
NRx: 1,333 {vs 1,561; -14.61%}
Monthly Retail TRx Market Share: 43.33% vs 38.93% --- ATH
Monthly Retail NRx Market Share: 44.81% vs 39.92% --- ATH
Monthly Retail Refills Market Share: 42.15% vs 38.20% --- ATH
Scripts Update for Week Ending 01/03
ATH Across the Board
V NRx continuing the increase, now 8 weeks in a row NRx of V in the GREEN
V
TRx: 40,285 {vs 37,687; +6.89%} Sector +6.00% --- ATH
NRx: 18,440 {vs 17,675; +4.33%} Sector +5.36% --- ATH
Ref: 21,845 {vs 20,012; +9.16%} Sector +6.53% --- ATH
GenL
TRx: 49,738 {vs 47,262; +5.24%}
NRx: 21,810 {vs 20,521; +6.28%}
L
TRx: 958 {vs 881; +8.74%}
NRx: 320 {vs 311; +2.89%}
V TRx Market Share: 44.28% vs 43.91% --- ATH
V NRx Market Share: 45.45% vs 45.90% --- 2nd ATH
V Ref Market Share: 43.33% vs 42.29% --- ATH
Great Scripts
Numbers to follow soon
Scripts Update for Week Ending 22/02
Short Week (President Day), V beating the Market Across the Board
ATH Numbers in NRx – 2nd ATH in TRx
ATH Across the Board in Market Share
GL continuing the decrease, now 6 weeks in a row GL in the RED
V
TRx: 37,687 {vs 37,934; -0.65%} Sector -2.15% --- 2nd ATH
NRx: 17,675 {vs 17,624; +0.29%} Sector -1.95% --- ATH
Ref: 20,012 {vs 20,310; -1.47%} Sector -2.32% --- 3rd ATH
GenL
TRx: 47,262 {vs 48,843; -3.24%}
NRx: 20,521 {vs 21,312; -3.71%}
L
TRx: 881 {vs 942; -6.48%}
NRx: 311 {vs 337; -7.72%}
V TRx Market Share: 43.91% vs 43.24% --- ATH
V NRx Market Share: 45.90% vs 44.88% --- ATH
V Ref Market Share: 42.29% vs 41.92% --- ATH
Scripts Tomorrow
Last week was a short week (President's Day), looking at figures for the same period in previous years, V numbers are almost flat to negative (TRx & NRx negative ~0.5%)
Same goes for the whole sector (TRx -0.5% & NRx -2%)
Let's wait and see tomorrow and hopefully it will be a positive surprise for V while GL continue the downtrend
From 10K
New Lipid Compounds and other Preclinical Programs
We are also considering development of other next generation compounds based on our internal lipid science expertise, including potential
combination and derivative therapies.
In August 2013, we completed dosing of AMR102, a fixed dose combination of Vascepa and a leading statin product. The study is a randomized,
open-label, single-dose, 4-way cross-over study to continue testing of the relative bioavailability of AMR102 capsules, Vascepa capsules with the selected
statin taken concomitantly, Vascepa taken alone and the selected statin taken alone. The results of this study support the feasibility of AMR102. We have
suspended additional development of AMR102 pending FDA approval of label expansion of Vascepa, anticipated to occur no sooner than after FDA review
of the results from the REDUCE-IT study.
We believe that Vascepa and other lipid-based compositions may have an impact on a number of biological factors in the body such as antiinflammatory mechanisms, cell membrane composition and plasticity, triglyceride levels and regulation of glucose metabolism. Currently all other
development activities are at formulation or pre-clinical stages
BB
Sure you have more % increase after short weeks, but yeah on average this is one of the top week-on-week (normal weeks)
But let me put it this way, V never had 7 consecutive NRx positive reading (i.e 7 weeks in a row, from Week ending 04/01/2019 till 15/02/2019) that were always POSITIVE & INCREASING & usually Q1 is a slow quarter :):)
On the other hand, GL never had 5 consecutive TRx negative reading (Week ending 18/01/19 till 15/02/19)
Next week will be interesting since it is a short week (president day), so let's see how thing evolve. Historically numbers should be either almost flat ~+0.4% down to ~-2.2%
NRx
To put things into perspective, well we haven't seen the Sector's total NRx >39K from September-2014
V is being prescribed more and more and in parallel it is increasing the Sector's number and gaining a bigger market share. As mentioned before, it's a double positive effect
Scripts Update for Week Ending 15/02
Sorry all, couldn’t resist a small laugh. Amazing Numbers across the board
ATH Numbers
V @ ATH & GL decreasing for the past 5 weeks (from week ending 11/01/2019)
V
TRx: 37,934 {vs 36,875; +2.87%} Sector +0.27% --- ATH
NRx: 17,624 {vs 16,563; +6.41%} Sector +2.34% --- ATH
Ref: 20,310 {vs 20,312; -0.01%} Sector -1.36% {ATH=20,312} --- 2nd ATH
GenL
TRx: 48,843 {vs 49,638; -1.60%}
NRx: 21,312 {vs 21,457; -0.68%}
L
TRx: 942 {vs 974; -3.29%}
NRx: 337 {vs 355; -5.07%}
V TRx Market Share: 43.24% vs 42.15% --- ATH
V NRx Market Share: 44.88% vs 43.16% --- ATH
V Ref Market Share: 41.92% vs 41.36% --- ATH
Scripts Today, Super Disappointing Numbers. I was expecting a positive increase not a decrease while GL is up. Numbers to follow
Cardio
I really appreciate your feedback and follow and i would like to thank you all for your inputs.
"I calculated your 10 year risk at 3.2% I assumed you have no diabetes, family history of premature CAD, not smoking and have normal blood pressures,"
Well the bad lipid numbers are mainly hereditary so i have to accept that i need to take the medicine at all time.
No diabetes & premature CAD in the family
I don't exercise a lot and this needs to be changed in due time
My blood pressure is normal and stable at all time
I do not have excess weight, it's the opposite, weight is thin (~70kg & 180cm), been trying for ages to increase my weight but it ain't working :):) so it has nothing to do with a diet or changing my food to lower the numbers
I do smoke and also this needs to be changed
Spoke with my Cardio last night and starting tomorrow Crestor 20 + V
will repeat my tests in 3M and hopefully things will be more positive
Gonna do my own V+Statin study and im sure it will be super positive
Regards to all and thanks again for all the feedback, inputs and comments
Cardio,
Oh WOW
And i thought that my percentile is totally the other way around i.e there is only 14% in better shape than me and 86 are worse
Oops, thats scary now :)
Thanks for the advise and feedback
Thank you Cardio
Yup born in 81, 86th percentile for my age
Btw, what do they mean when they say "Aorta measures 31mm at the level of the right pulmonary artery. The pulmonary trunk measures 22mm"
Thanks again
Cardio,
I would appreciate your feedback if possible
I had high Cholesterol, from a long time. Used to take Crestor 20mg but been a 1.5year without any medicine, a personal decision.
Just got my latest test results:
HDL 43
LDL 229
Total 304
Chol/HDL 7.07
Trig 252
And at the request of my Cardiologist i did CT Calcium Score which is 4.4 & Aorta measures 31mm at the level of the right pulmonary artery. The pulmonary trunk measures 22mm
I am seeing my Dr. next week in order to decide on my medication.
I would appreciate your opinion regarding teh results above and do you think i should be back on Crestor 10mg or 20mg + Vascepa
Thank you in advance
Scott Gottlieb on Twitter, Interesting Read
Dietary supplements such as vitamins, minerals or herbs are regularly used by 3 out of 4 consumers and can be beneficial. In today's FDA Sunday Tweetorial I review FDA's efforts to ensure safety of these products through steps to modernize our oversight
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631065.htm
Today, we’re announcing new steps we intend to advance to achieve these twin goals. These steps include communicating to the public as soon as possible when there is a concern about a dietary supplement on the market, ensuring that our regulatory framework is flexible enough to adequately evaluate product safety while also promoting innovation, continuing to work closely with our industry partners, developing new enforcement strategies and continuing to engage in a public dialogue to get valuable feedback from dietary supplement stakeholders.
That’s why today we are announcing a new plan for policy advancements with the goal of implementing one of the most significant modernizations of dietary supplement regulation and oversight in more than 25 years.
It’s clear to me that dietary supplements play an important role in our lives as we strive to stay healthy. It’s also clear that the U.S. Food and Drug Administration plays an important role in helping consumers make use of safe, high-quality dietary supplements while also protecting Americans from the potential dangers of products that don’t meet the agency’s standards for marketing.
In the 25 years since Congress passed the Dietary Supplement Health and Education Act (DSHEA), the law that transformed the FDA’s authority to regulate dietary supplements, the dietary supplement market has grown significantly. What was once a $4 billion industry comprised of about 4,000 unique products, is now an industry worth more than $40 billion, with more than 50,000 – and possibly as many as 80,000 or even more – different products available to consumers
As the popularity of supplements has grown, so have the number of entities marketing potentially dangerous products or making unproven or misleading claims about the health benefits they may deliver.
Making healthy choices about diets can have a significant and positive impact on Americans’ health. To be able to make those choices with respect to dietary supplements, consumers need to have access to safe, well-manufactured, and appropriately labeled products. One of my top goals is ensuring that we achieve the right balance between preserving consumers’ access to lawful supplements, while still upholding our solemn obligation to protect the public from unsafe and unlawful products, and holding accountable those actors who are unable or unwilling to comply with the requirements of the law.
Legitimate industry benefits from a framework that inspires the confidence of consumers and providers. Patients benefit from products that meet high standards for quality.
I’m concerned that changes in the supplement market may have outpaced the evolution of our own policies and our capacity to manage emerging risks. To continue to fulfill our public health obligations we need to modernize and strengthen our overall approach to these products. Toward these goals, the FDA is committing to new priorities when it comes to our oversight of dietary supplements at the same time that we carefully evaluate what more we can do to meet the challenge of effectively overseeing the dietary supplement market while still preserving the balance struck by DSHEA.
......
Scripts Update for Week Ending 08/02
ATH Across the Board in Numbers & Market Share
V @ ATH and GL decreasing for the past 4 weeks (from week ending 11/01/2019)
V
TRx: 36,875 {vs 35,658; +3.41%} Sector +0.25% --- ATH
NRx: 16,563 {vs 16,332; +1.41%} Sector -0.25% --- ATH
Ref: 20,312 {vs 19,326; +5.10%} Sector +0.65% --- ATH
GenL
TRx: 49,638 {vs 50,656; -2.01%}
NRx: 21,457 {vs 21,772; -1.45%}
L
TRx: 974 {vs 952; +2.31%}
NRx: 355 {vs 369; -3.79%}
V TRx Market Share: 42.15% vs 40.86% --- ATH
V NRx Market Share: 43.16% vs 42.45% --- ATH
V Ref Market Share: 41.36% vs 39.61% --- ATH
ATH Across the Board in Numbers & Market Share
V @ ATH and GL decreasing for the past 4 weeks (from week ending 11/01/2019)
January-2019 vs. January-2018 (Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board --- Way Way Way better than my expectation yesterday
V
TRx: 151,870 {vs 108,192; +40.37%} – Sector +9.79% -- ATH
NRx: 65,725 {vs 41,223; +59.44%} – Sector +20.19% -- ATH
Ref: 86,145 {vs 66,969; +28.63%} – Sector +3.27% -- 2nd ATH
Gen L
TRx: 234,040 {vs 229,587; +1.94%}
NRx: 97,351 {vs 88,073; +10.53%}
L
TRx: 4,250 {vs 17,589; -75.84%}
NRx: 1,561 {vs 7,684; -79.69%}
V Jan-2019 Retail ONLY TRx Market Share: 38.93% vs 30.45% in Jan-2018 --- ATH
V Jan-2019 Retail ONLY NRx Market Share: 39.92% vs 30.09% in Jan-2018 --- ATH
V Jan-2019 Retail ONLY Ref Market Share: 38.20% vs 30.67% in Jan-2018 --- ATH
Total Monthly Retail ONLY Data January-2019
ATH in TRx & NRx Numbers & Across the Board in Market Share
V
TRx: 151,870 {vs 144,510; +5.09%} – Sector +0.63% -- ATH
NRx: 65,725 {vs 58,130; +13.07%} – Sector +7.97% -- ATH
Ref: 86,145 {vs 86,380; -0.27%} – Sector -4.13% -- 2nd ATH
Gen L
TRx: 234,040 {vs 238,870; -2.02%}
NRx: 97,351 {vs 92,841; +4.86%}
L
TRx: 4,250 {vs 4,335; -1.96%}
NRx: 1,561 {vs 1,510; +3.38%}
Monthly Retail TRx Market Share: 38.93% vs 37.27% --- ATH
Monthly Retail NRx Market Share: 39.92% vs 38.12% --- ATH
Monthly Retail Refills Market Share: 38.20% vs 36.72% --- ATH
Amazing Year-On-Year Increase Across the Board --- Way Way Way better than my expectation yesterday for V numbers & Spot On for Sector's Numbers
Monthly Retail Numbers
Super excited about January Monthly Retail Numbers Tomorrow vs those back in 2018.
If the weekly numbers are used as a measure, well we should see an increase of >35% in TRx & >40% in NRx
The most interesting part is that Jan-2019 vs Jan-2018 Sector Numbers should also have an increase of ~10% TRx & ~17% NRx
Meaning that V is actually increasing its Market Share and in Parallel increasing the whole sector numbers which will have Double Positive Effect
Long & Strong since 2012
Stock Price
Whats up with the stock price bid @ $17.75 & Ask @$17.95 ??
Scripts Update for Week Ending 01/02
Great Numbers ATH TRx & NRx & ATH across the board in Market Share despite the Polar Vortex negative effect
V
TRx: 35,658 {vs 33,661; +5.93%} Sector +1.79% --- ATH
NRx: 16,332 {vs 14,959; +9.18%} Sector +4.10% --- ATH
Ref: 19,326 {vs 18,702; +3.34%} Sector +0.04%
GenL
TRx: 50,656 {vs 51,168; -1.00%}
NRx: 21,772 {vs 21,674; +0.45%}
L
TRx: 952 {vs 902; +5.54%}
NRx: 369 {vs 324; +13.89%}
V TRx Market Share: 40.86% vs 39.26% --- ATH
V NRx Market Share: 42.45% vs 40.48% --- ATH
V Ref Market Share: 39.61% vs 38.34% --- ATH
Great Numbers ATH TRx & NRx & ATH across the Board in Market Share despite the Polar Vortex negative effect
Scripts Tomorrow
Tomorrow's scripts numbers will definitely be better than previous weeks but i am not expecting an ATH mainly due to the Polar Vortex that hit several areas last week. A positive surprise and ATH will be amazing, but i highly doubt it JMO
Scripts Update for Week Ending 25/01
Short Week – Market Share & NRx what counts. ATH Across the Board in Market Share – NRx POSITIVE while the sector NRx is down
V
TRx: 33,661 {vs 34,195; -1.56%} Sector -3.23%
NRx: 14,959 {vs 14,862; +0.65%} Sector -1.52% -- 2nd ATH
Ref: 18,702 {vs 19,333; -3.26%} Sector -4.49%
GenL
TRx: 51,168 {vs 53,437; -4.25%}
NRx: 21,674 {vs 22,311; -2.86%}
L
TRx: 902 {vs 964; -6.43%}
NRx: 324 {vs 354; -8.47%}
V TRx Market Share: 39.26% vs 38.60% --- ATH
V NRx Market Share: 40.48% vs 39.60% --- ATH
V Ref Market Share: 38.34% vs 37.86% --- ATH
ACC - March-2019
I am not sure if this was posted before, but as can be seen in the below link: "In addition to the late-breaking clinical trials, the ACC/American Heart Association Guideline on the Primary Prevention of Cardiovascular Disease will also be released at the meeting."
IMO, V will be on the guideline and will be practice of care before even getting FDA approval/Label change
https://www.healio.com/cardiology/chd-prevention/news/online/%7bba58492b-6f56-4cf3-a0ca-b641f485b561%7d/acc-late-breaking-clinical-trials-announced
Always
I disagree with you 100%
It has nothing to do with getting a label change or being acquired.
The scripts mirror previous years increase/decrease for the same period.
In few weeks, all will be clear especially in terms of insurance coverage and deductibles and it will kick start from there
A more important point to note is that during the ACC in March-2019, in addition to the late-breaking clinical trials, the ACC/American Heart Association Guideline on the Primary Prevention of Cardiovascular Disease will also be released at the meeting
My feeling is that V will be on the guideline and will be practice of care before even getting FDA approval/Label change
Scripts Update for Week Ending 18/01
ATH in NRx Market Share. 2nd ATH in TRx & Refill Market Share
This week's numbers go in parallel as previous years for anyone out there concerned with the small drop
V
TRx: 34,195 {vs 34,518; -0.94%} Sector -0.66% -- 5th ATH
NRx: 14,862 {vs 14,617; +1.68%} Sector +1.01% -- 3rd ATH
Ref: 19,333 {vs 19,901; -2.85%} Sector -1.86% -- 7th ATH
GenL
TRx: 53,437 {vs 53,690; -0.47%}
NRx: 22,311 {vs 22,148; +0.74%}
L
TRx: 964 {vs 981; -1.73%}
NRx: 354 {vs 385; -8.05%}
V TRx Market Share: 38.60% vs 38.70% --- 2nd ATH
V NRx Market Share: 39.60% vs 39.25% --- ATH
V Ref Market Share: 37.86% vs 38.24% --- 2nd ATH
Full Year-2018 vs. Full Year-2017 ( Retail + Inst. Data )
Amazing Yearly Increase & it goes without saying that it is ATH Numbers & Market Share Year-On-Year Comparison
V
TRx 1Y-2018 vs 1Y-2017 +20.23% – Sector +4.30%
NRx 1Y-2018 vs 1Y-2017 +20.83% – Sector +7.55%
Refills 1Y-2018 vs 1Y-2017 +19.88% – Sector +2.56%
Gen L
TRx 1Y-2018 vs 1Y-2017 -1.97%
NRx 1Y-2018 vs 1Y-2017 +2.29%
Refills 1Y-2018 vs 1Y-2017 -4.16%
L
TRx 1Y-2018 vs 1Y-2017 -0.63%
NRx 1Y-2018 vs 1Y-2017 -3.88%
Refills 1Y-2018 vs 1Y-2017 -+1.28%
V 1Y-2018 Retail + Inst. TRx Market Share: 32.30% vs 28.02% in 1Y-2017
V 1Y-2018 Retail + Inst. Data NRx Market Share: 33.22% vs 29.57% in 1Y-2017
V 1Y-2018 Retail + Inst. Data Refills Market Share: 31.80% vs 27.20% in 1Y-2017
December-2018 vs. December-2017 (Retail + Inst. Data)
V
TRx: 152,677 {vs 122,386; +24.75%} -- Sector +7.61% --- ATH
NRx: 58,130 {vs 40,966; +41.90%} – Sector +16.14% --- ATH
Ref: 94,547 {vs 81,420; +16.12%} – Sector +0.91% --- ATH
Gen L
TRx: 264,647 {vs 253,424; +4.43%}
NRx: 92,841 {vs 83,175; +11.62%}
L
TRx: 6,332 {vs 17,887; -64.60%}
NRx: 1,510 {vs 7,145; -78.87%}
V December-2018 Retail+Inst. TRx Market Share: 36.04% vs 31.09% in December-2017 – ATH
V December-2018 Retail+Inst. NRx Market Share: 38.12% vs 31.20% in December-2017 -- ATH
V December-2018 Retail+Inst. Refill Market Share: 34.87% vs 31.03% in December-2017 – ATH
Total Monthly Retail + Institutional Data December-2018
ATH Across the board in Market Share & Numbers
V
TRx: 152,677 {vs 144,728; +5.49%} -- Sector +1.38% --- ATH
(Inst # 8,167 vs 7,458; +9.51% -- Inst Sec -3.33% -- Inst Mkt Sh 22.72% vs 20.06%)
NRx: 58,130 {vs 57,035; +1.92%} – Sector -0.86% --- ATH
Ref: 94,547 {vs 87,693; +7.82%} – Sector +2.68% --- ATH
Gen L
TRx: 264,647 {vs 266,595; -0.73%}
(Inst # 25,777 vs 27,495; -6.25%)
NRx: 92,841 {vs 95,259; -2.54%}
L
TRx: 6,332 {vs 6,566; -3.56%}
(Inst # 1,997 vs 2,226; -10.29%)
NRx: 1,510 {vs 1,507; +0.20%}
V Monthly Retail + Inst. TRx Market Share: 36.04% vs 34.63% -- ATH
V Monthly Retail + Inst. NRx Market Share: 38.12% vs 37.08% -- ATH
V Monthly Retail + Inst. Ref Market Share: 34.87% vs 33.21% -- ATH
Hspooner
You have mentioned this before, but till now, nothing has been posed on the bloomberg terminal where i get the data from about any change in reporting
Regards
Scripts Update for Week Ending 11/01
Good numbers taking into consideration the delays that might be happening with new insurance plans at the beginning of the year
ATH Across the Board in Market Share. 2nd ATH in TRx & Refill Numbers. 3rd ATH in NRx Numbers
V
TRx: 34,518 {vs 30,956; +11.51%} Sector +7.05% -- 2nd ATH
NRx: 14,617 {vs 11,273; +29.66%} Sector +22.74% -- 3rd ATH
Ref: 19,901 {vs 19,683; +1.11%} Sector -1.90% -- 2nd ATH
GenL
TRx: 53,690 {vs 51,477; +4.30%}
NRx: 22,148 {vs 18,703; +18.42%}
L
TRx: 981 {vs 880; +11.48%}
NRx: 385 {vs 291; +32.30%}
V TRx Market Share: 38.70% vs 37.16% --- ATH
V NRx Market Share: 39.35% vs 37.25% --- ATH
V Ref Market Share: 38.24% vs 37.11% --- ATH
1Y-2018 vs. 1Y-2017 (Retail ONLY Data)
Great Yearly Increase & it goes without saying that it is ATH Numbers & Market Share Year-On-Year Comparison
V
TRx 1Y-2018 vs 1Y-2017 +19.29% – Sector +2.96%
NRx 1Y-2018 vs 1Y-2017 +20.83% – Sector +7.55%
Refills 1Y-2018 vs 1Y-2017 +18.30% – Sector +0.15%
Gen L
TRx 1Y-2018 vs 1Y-2017 -3.37%
NRx 1Y-2018 vs 1Y-2017 +2.29%
Refills 1Y-2018 vs 1Y-2017 -6.75%
L
TRx 1Y-2018 vs 1Y-2017 -8.07%
NRx 1Y-2018 vs 1Y-2017 -3.88%
Refills 1Y-2018 vs 1Y-2017 -10.83%
V 1Y-2018 Retail ONLY TRx Market Share: 33.20% vs 28.65% in 1Y-2017
V 1Y-2018 Retail ONLY NRx Market Share: 33.22% vs 29.57% in 1Y-2017
V 1Y-2018 Retail ONLY Refills Market Share: 33.19% vs 28.10% in 1Y-2017
Total Monthly Retail ONLY Data December-2018
ATH Across the Board in Numbers & Market Share
V
TRx: 144,510 {vs 137,270; +5.27%} – Sector +1.84% -- ATH
NRx: 58,130 {vs 57,035; +1.92%} – Sector -0.86% -- ATH
Ref: 86,380 {vs 80,235; +7.66%} – Sector +3.67% -- ATH
Gen L
TRx: 238,870 {vs 239,100; -0.10%}
NRx: 92,841 {vs 95,259; -2.54%}
L
TRx: 4,335 {vs 4,340; -0.12%}
NRx: 1,510 {vs 1,507; +0.20%}
Monthly Retail TRx Market Share: 37.27% vs 36.06% --- ATH
Monthly Retail NRx Market Share: 38.12% vs 37.08% --- ATH
Monthly Retail Refills Market Share: 36.72% vs 35.36% --- ATH